Protalix BioTherapeutics Announces Pricing of its Upsized Public Offering of Common StockPRNewsWire • 02/12/21
Protalix BioTherapeutics Perks Up On Alidornase Alfa Licensing Pact In Respiratory ConditionsBenzinga • 02/11/21
Protalix BioTherapeutics Enters into an Exclusive Partnership with SarcoMed USA to Develop alidornase alfa for the Treatment of Pulmonary Sarcoidosis and Related Respiratory Diseases Via Inhaled DeliveryPRNewsWire • 02/11/21
Protalix BioTherapeutics and Chiesi Global Rare Diseases Present Key Clinical Data of Pegunigalsidase Alfa for the Treatment of Fabry Disease at the 17th Annual WORLDSymposium™ 2021PRNewsWire • 02/10/21
Protalix BioTherapeutics Announces Presentations at the 17th Annual WORLDSymposium™ 2021PRNewsWire • 02/01/21
Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in JanuaryPRNewsWire • 01/04/21
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry DiseasePRNewsWire • 12/30/20
FDA Decision For Protalix Postponed Due To Covid, But Fundamentals Remain StrongSeeking Alpha • 12/28/20
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Extension of PDUFA Date for Pegunigalsidase Alfa for the Proposed Treatment of Fabry DiseasePRNewsWire • 11/27/20
Protalix BioTherapeutics to Present at the H.C. Wainwright 6th Annual Israel ConferencePRNewsWire • 11/05/20
Protalix BioTherapeutics, Inc. (PLX) CEO Dror Bashan on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/01/20
Protalix BioTherapeutics to Reschedule Third Quarter 2020 Financial Results and Business Update Call for Friday, October 30PRNewsWire • 10/29/20
Protalix BioTherapeutics Reports Third Quarter 2020 Financial Results and Provides Business UpdatePRNewsWire • 10/29/20
Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Launch of Expanded Access Program in the United States for Pegunigalsidase Alfa for the Proposed Treatment of Fabry DiseasePRNewsWire • 10/02/20
Protalix BioTherapeutics Regains Compliance with NYSE American Continued Listing StandardsPRNewsWire • 09/08/20
Protalix BioTherapeutics Announces Completion of the Treatment Period for its Phase III BRIGHT Clinical Trial of Pegunigalsidase Alfa (PRX-102) for the Proposed Treatment of Fabry DiseasePRNewsWire • 08/24/20
Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce U.S. Food and Drug Administration Acceptance of Biologics License Application (BLA) for Pegunigalsidase Alfa for the Proposed Treatment of Fabry Disease and Grants Priority ReviewPRNewsWire • 08/11/20
Protalix BioTherapeutics, Inc.'s (PLX) CEO Dror Bashan on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/10/20
Protalix BioTherapeutics to Present at the BTIG Virtual Biotechnology Conference 2020PRNewsWire • 08/06/20
Protalix BioTherapeutics to Hold Second Quarter 2020 Financial Results and Business Update Conference Call on August 10, 2020PRNewsWire • 08/03/20
